New insider activity at Altimmune ( (ALT) ) has taken place on December 23, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Altimmune has caught insider attention as Director John Gill recently purchased 12,500 shares of the company’s stock in a transaction valued at $51,250. This insider buy may signal confidence in Altimmune’s outlook, drawing investor interest to both the size of the acquisition and the director’s increased stake in the company.
Recent Updates on ALT stock
Over the last 24 hours, Altimmune’s stock dropped about 21% to $3.98 despite the company reporting what it characterized as positive 48‑week topline Phase 2b IMPACT data for its lead MASH candidate, pemvidutide. The trial showed statistically significant improvements versus placebo in key non‑invasive fibrosis and liver‑health markers (such as ELF and liver stiffness), sustained and dose‑responsive antifibrotic signals from week 24 to 48, incremental weight loss at the higher dose without plateau, and a favorable tolerability profile with fewer discontinuations than placebo. Altimmune also recently aligned with the FDA on Phase 3 trial parameters and the potential use of the AIM‑MASH AI pathology tool, while shoring up its balance sheet via an at‑the‑market equity program. Analysts’ stance and target revisions referenced in the articles are driven by balancing these encouraging clinical and regulatory developments and pemvidutide’s differentiated profile against Altimmune’s ongoing profitability and cash‑flow challenges, the need for substantial further funding to execute Phase 3, and the increasingly crowded and competitive MASH treatment landscape, which together temper enthusiasm even in the face of supportive trial data. Options activity has been elevated and mixed, with both heavy put and call flows and sharply higher implied volatility, reflecting uncertainty over how the Phase 2b results and funding needs will ultimately translate into commercial and valuation outcomes.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
Altimmune’s overall stock score is primarily impacted by its poor financial performance, with severe profitability and cash flow issues. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings. Despite these challenges, the positive sentiment from the earnings call and corporate events provides some optimism for future growth.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
YTD Price Performance: -41.77%
Average Trading Volume: 3,514,684
Technical Sentiment Signal: Sell
Current Market Cap: $406.9M